Bidders for the U.S. portion of Boehringer Ingelheim's Roxane Labs unit include Hikma Pharmaceuticals (OTCPK:HKMPY), Mallinckrodt (MNK +0.7%) and Perrigo (PRGO +1%). The generics business could fetch as much as $2.2B according to sources close to the matter. A deal could close in a matter of weeks.
Hikma Pharmaceuticals (HKMPF) has agreed to buy the U.S. generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300M, as it attempts to boost its "injected medicine" market share.
The company will pay $225M upfront for the assets of Boehringer's Bedford Laboratories and another $75M over the course of five years based on the performance of the drugs.
May 28, 2014, 8:27 AM
Nov. 23, 2011, 1:59 PM
Aeterna Zentaris (AEZS +1.8%) gains after saying it's signed an exclusive agreement for the registration and marketing of perifosine in the Middle East and North Africa with Hikma Pharmaceuticals (HKMPY.PK).